无锡帕母医疗技术有限公司 Mediaroom

Pulnovo Medical Receives two IDE approvals for PADN system's clinical trials with CMS coverage

SHANGHAI, Sept. 12, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized leader in medical d...

2025-09-12 18:23 1806

Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therap...

2025-08-25 16:42 1554

Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners

HONG KONG, May 20, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical d...

2025-05-20 16:53 2325

Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing

SHANGHAI, March 3, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical d...

2025-03-03 08:00 2448

Pulnovo Medical Announces First Enrollment in Singapore for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

SHANGHAI, Aug. 9, 2024 /PRNewswire/ -- Pulnovo Medical Limited,a globally recognized device pioneer...

2024-08-09 17:09 5428

Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association) Corporate Committee

SHANGHAI, July 9, 2024 /PRNewswire/ -- Pulnovo Medical, a globally recognized device pioneer in the...

2024-07-09 20:00 2555

Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

SHANGHAI, July 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pionee...

2024-07-02 19:10 2902

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pionee...

2024-01-02 20:30 2706

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment

SHANGHAI, March 28, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platfor...

2023-03-28 20:30 2299

Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hypertension (PAH) Treatment

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform...

2023-02-28 10:19 2140

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

SHANGHAI, Jan. 14, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform...

2023-01-14 22:00 4378

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

SHANGHAI, Jan. 4, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform,...

2023-01-04 10:46 2702

Pulnovo Medical will be attending JPM Healthcare Conference 2023

SHANGHAI, Dec. 24, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovati...

2022-12-24 20:00 4379

Pulnovo Medical Inhales Tens of Millions Dollars Funding to Accelerate Global Growth

SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM (From Ope...

2022-11-07 20:30 3276

TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH)

SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platfor...

2022-09-23 20:30 2420

Latest News

Pulnovo Medical Receives two IDE approvals for PADN system's clinical trials with CMS coverage

Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners

Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing

Pulnovo Medical Announces First Enrollment in Singapore for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association) Corporate Committee

Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment

Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hypertension (PAH) Treatment

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

Pulnovo Medical will be attending JPM Healthcare Conference 2023

Pulnovo Medical Inhales Tens of Millions Dollars Funding to Accelerate Global Growth

TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH)

Pulnovo Medical Released Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH)

Pulnovo Medical Concludes Successfully the First Steering Committee Meeting

Pulnovo Medical Limited's PADN Technology Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH

Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial

Pulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board